Twitter LinkedIn
    Saturday, March 25
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Mergers & Acquisitions»Partners Group to acquire Pharmathen from BC Partners
    Mergers & Acquisitions

    Partners Group to acquire Pharmathen from BC Partners

    July 19, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Global private markets firm Partners Group has, on behalf of its clients, agreed to acquire Pharmathen, a European pharmaceutical company, from international investment firm BC Partners.

    The transaction values the Company at an enterprise value of around EUR1.6 billion. Founded in 1969, Pharmathen is a contract development and manufacturing organisation (CDMO) specialised in advanced drug delivery technologies for complex generic pharmaceutical products. With best-in-class Research & Development (R&D) capabilities, the Company is a specialist in the development of “sustained release” technologies that improve patient compliance, such as long-acting injectables, slow-releasing oral medicines and ophthalmics. Pharmathen’s differentiated B2B model attracts a blue-chip customer base of more than 215 generic pharmaceutical companies, which it serves from two US/EU-approved manufacturing facilities in Greece. The Company’s highly diversified product portfolio of c80 commercialised products is accessed by patients in more than 85 countries worldwide.

    Partners Group will work closely with Pharmathen’s management team, led by Chief Executive Officer Dimitris Kadis, on initiatives to scale the business in Europe and globally. In particular, Partners Group will support the Company to accelerate its expansion in the US, by building out its on-the-ground presence. Additionally, Partners Group will draw on its deep sector expertise in healthcare and pharmaceuticals, as well as its experience in state-of-the-art manufacturing, to support the development of innovative technology platforms that improve patient compliance and lead to better treatment outcomes.

    Pascal Noth, Managing Director, Private Equity Europe, Partners Group, says: “Pharmathen is very well-regarded by the broader pharmaceutical industry as an innovative and forward-thinking company. It is a mission-critical partner to its B2B clients whose advanced pharmaceutical technologies create real societal impact and optimise treatment outcomes for patients. Partners Group will lend its operational expertise to support Pharmathen as it expands to meet increasing demand for affordable Generics and positions for long-term, sustainable growth. We are delighted to back Dimitris and his talented management team and look forward to working with them.”

    Read more/Source: Private Equity Wire

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Capital Mergers and acquisitions PE Insider Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    UBS Agrees to Buy Credit Suisse for $3 Billion in Historic Deal – Copy

    March 19, 2023

    UBS Agrees to Buy Credit Suisse for $3 Billion in Historic Deal

    March 19, 2023

    Euroclear moves into $9.8 trillion private asset market with Goji buy

    December 21, 2022

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    Comments are closed.

    Other Articles

    Bridewell Consulting attracts private equity backing

    March 26, 2021

    CPPIB joins Bain Private Equity and Bain Credit to acquire stake in IIFL Wealth

    April 27, 2022

    Alan Howard’s crypto platform attracts investment from Goldman Sachs and Barclays

    May 16, 2022

    Carlyle Flagship Fund Expected to Reach $17bn by Midyear

    January 25, 2022

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?